menu
    • menu
    [{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"Pharmadrug Production GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Cepharanthine","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sairiyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sairiyo Therapeutics \/ PharmaDrug","highestDevelopmentStatusID":"1","companyTruncated":"Sairiyo Therapeutics \/ PharmaDrug"},{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cepharanthine","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sairiyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sairiyo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sairiyo Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Cepharanthine

    Menu

    Cepharanthine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sairiyo Therapeutics

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Sairiyo Therapeutics

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cepharanthine

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PharmaTher's Sairiyo Advances Development of Cepharanthine for Phase 1 Study in Australia

                            Details : PD-001 (cepharanthine) is an approved, oral, small molecule natural product candidate. It is being evaluated for the treatment of cancer and covid-19 infection.

                            Brand Name : PD-001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 21, 2024

                            Lead Product(s) : Cepharanthine

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sairiyo Therapeutics

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Sairiyo Therapeutics

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cepharanthine

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Pharmadrug Production GmbH

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            PharmaDrug Enters Definitive Agreement to Acquire Sairiyo Therapeutics

                            Details : Sairiyo is advancing the clinical development of its lead drug candidate, Cepharanthine, a repurposed and reformulated naturally derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 25, 2021

                            Lead Product(s) : Cepharanthine

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Pharmadrug Production GmbH

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth